The First Amendment, In Your Medicine Cabinet

Loeb & Loeb LLP partner Scott Liebman is quoted on the paradigm shift taking place in the life sciences industry with regard to promotion of prescription drugs.  He discusses First Amendment challenges to restrictions on off-label communications, evolving transparency in pricing and payments, the Affordable Care Act and other key regulatory developments that could fundamentally change the sales of drugs, devices and biologics.

Click here to read the full article on Forbes.com.